Sublingual Misoprostol in Reduction of Caesarean Blood Loss
Status:
Not yet recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Caesarean delivery is inevitably associated with a higher amount of blood loss vis-à-vis
primary postpartum haemorrhage, when compared to vaginal delivery. Oxytocin use in tropical
developing countries for the reduction blood loss at caesarean section have been met with
challenges of ineffectiveness due to poor transportation, inadequate storage and drug
adulteration. Therefore, there is a need for an effective, temperature stable uterotonic with
a lesser risk of adulteration. The study is aimed at evaluating the effectiveness and safety
of adjunctive sublingual misoprostol in reducing intraoperative blood loss at caesarean
section.